Shufro Rose & Co. LLC cut its position in Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 42.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,525 shares of the company’s stock after selling 9,300 shares during the quarter. Shufro Rose & Co. LLC’s holdings in Henry Schein were worth $1,092,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also made changes to their positions in the company. Covestor Ltd acquired a new stake in Henry Schein in the fourth quarter valued at $35,000. National Bank of Canada FI acquired a new stake in Henry Schein in the fourth quarter valued at $42,000. Quent Capital LLC acquired a new stake in shares of Henry Schein during the fourth quarter worth $47,000. Dupont Capital Management Corp raised its holdings in shares of Henry Schein by 46.2% during the first quarter. Dupont Capital Management Corp now owns 611 shares of the company’s stock worth $53,000 after purchasing an additional 193 shares during the period. Finally, Hazlett Burt & Watson Inc. acquired a new stake in shares of Henry Schein during the first quarter worth $89,000. 94.30% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at Henry Schein
In related news, EVP Gerald A. Benjamin sold 11,489 shares of the firm’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $85.47, for a total transaction of $981,964.83. Following the transaction, the executive vice president now owns 95,616 shares of the company’s stock, valued at $8,172,299.52. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.00% of the company’s stock.
Henry Schein Price Performance
Henry Schein (NASDAQ:HSIC – Get Rating) last posted its quarterly earnings results on Tuesday, August 2nd. The company reported $1.16 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.16. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.12 billion. Henry Schein had a net margin of 5.11% and a return on equity of 15.56%. The firm’s revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.11 earnings per share. Equities research analysts predict that Henry Schein, Inc. will post 4.85 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have weighed in on HSIC shares. The Goldman Sachs Group cut shares of Henry Schein from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $93.00 to $85.00 in a report on Thursday, July 21st. Stifel Nicolaus dropped their target price on shares of Henry Schein from $90.00 to $80.00 in a report on Friday, June 17th. William Blair reissued a “market perform” rating on shares of Henry Schein in a report on Tuesday, May 3rd. Barrington Research dropped their price objective on shares of Henry Schein from $102.00 to $99.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Piper Sandler dropped their price objective on shares of Henry Schein from $100.00 to $96.00 in a report on Tuesday. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $87.14.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
- Get a free copy of the StockNews.com research report on Henry Schein (HSIC)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.